# Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

> **NCT00006825** · PHASE1,PHASE2 · COMPLETED · sponsor: **NYU Langone Health**

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00006825
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2004-07
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006825, "Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00006825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*